Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

Screening Epidemiological Program on Compensation Evaluation of DM Type 2 Patients on OAD Monotherapy and Physicians Satisfaction of Their Usage

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01275794

Enrollment

1849

Registered

2011-01-12

Start date

2010-12-31

Completion date

2011-03-31

Last updated

2012-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 Diabetes

Brief summary

The purpose of the study is assessment of glycemic control and physicians satisfaction with results of DM2 OAD monotherapy

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients have an established diagnosis of T2D * Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program

Exclusion criteria

* Experience of therapy with two or more OADs and/or insulin therapy and/or incretin mimetics (exenatide) at any time before registration in the Program * Absence of changes in HbAc1 level during the last year before registration in the Program

Design outcomes

Primary

Measure	Time frame
To assess levels of compensation of T2D by HbA1c levels in patients on OAD monotherapy	1 visit within 4 month
To assess frequency of target levels of HbA1c ≤ 7% in patients with T2D during OAD monotherapy	1 visit within 4 month

Secondary

Measure	Time frame
To assess fasting glycemia in patients with T2D on OAD monotherapy	1 visit within 4 month
To assess postprandial levels of glycemia in patients with T2D during OAD monotherapy	1 visit within 4 month
To evaluate the physicians' satisfaction with the results of OAD monotherapy in patients with Typ 2 Diabetes (T2D)	1 visit within 4 month
To compare the results of OAD monotherapy in different groups of patients	1 visit within 4 month

Countries

Russia

Outcome results